BioMarin May Be On Cusp Of Profitability, With GALNS The Key Determining Factor
This article was originally published in The Pink Sheet Daily
Executive Summary
At the Canaccord Genuity Global Growth Conference, the rare disease-focused biotech reiterated its goal to reach profitability in the near future with five pipeline programs potentially augmenting a portfolio of four marketed products.